A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes

NCT04545515 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: ELX/TEZ/IVA
DRUG: IVA

Sponsor

Vertex Pharmaceuticals Incorporated